164 related articles for article (PubMed ID: 32350933)
21. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients.
Lin WM; Lewis JM; Filler RB; Modi BG; Carlson KR; Reddy S; Thornberg A; Saksena G; Umlauf S; Oberholzer PA; Karpova M; Getz G; Mane S; Garraway LA; Dummer R; Berger CL; Edelson RL; Girardi M
J Invest Dermatol; 2012 Jan; 132(1):188-97. PubMed ID: 21881587
[TBL] [Abstract][Full Text] [Related]
22. The pathogenesis of large cell transformation in cutaneous T-cell lymphoma is not associated with t(2;5)(p23;q35) chromosomal translocation.
Li G; Salhany KE; Rook AH; Lessin SR
J Cutan Pathol; 1997 Aug; 24(7):403-8. PubMed ID: 9274957
[TBL] [Abstract][Full Text] [Related]
23. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
25. Analysis of clonality in cutaneous T cell lymphoma and associated diseases.
Wood GS
Ann N Y Acad Sci; 2001 Sep; 941():26-30. PubMed ID: 11594579
[TBL] [Abstract][Full Text] [Related]
26. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
Kohnken R; Wen J; Mundy-Bosse B; McConnell K; Keiter A; Grinshpun L; Hartlage A; Yano M; McNeil B; Chakravarti N; William B; Bradner JE; Caligiuri MA; Porcu P; Mishra A
Blood; 2018 Feb; 131(7):771-781. PubMed ID: 29180399
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma.
Sandoval J; Díaz-Lagares A; Salgado R; Servitje O; Climent F; Ortiz-Romero PL; Pérez-Ferriols A; Garcia-Muret MP; Estrach T; Garcia M; Nonell L; Esteller M; Pujol RM; Espinet B; Gallardo F
J Invest Dermatol; 2015 Apr; 135(4):1128-1137. PubMed ID: 25405321
[TBL] [Abstract][Full Text] [Related]
28. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.
Stolearenco V; Levring TB; Nielsen HM; Lindahl L; Fredholm S; Kongsbak-Wismann M; Willerslev-Olsen A; Buus TB; Nastasi C; Hu T; Gluud M; Côme CRM; Krejsgaard T; Iversen L; Bonefeld CM; Grønbæk K; Met Ö; Woetmann A; Ødum N; Geisler C
Dermatology; 2021; 237(2):283-290. PubMed ID: 32799209
[TBL] [Abstract][Full Text] [Related]
29. [New insights into the pathogenesis and molecular understanding of cutaneous T-cell lymphomas].
Stadler R; Hain C
Dermatologie (Heidelb); 2022 Oct; 73(10):765-771. PubMed ID: 35960311
[TBL] [Abstract][Full Text] [Related]
30. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas.
Urosevic M; Willers J; Mueller B; Kempf W; Burg G; Dummer R
Blood; 2002 Jan; 99(2):609-17. PubMed ID: 11781245
[TBL] [Abstract][Full Text] [Related]
31. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
32. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
33. p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases.
Marrogi AJ; Khan MA; Vonderheid EC; Wood GS; McBurney E
J Cutan Pathol; 1999 Sep; 26(8):369-78. PubMed ID: 10551408
[TBL] [Abstract][Full Text] [Related]
34. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
35. Aberrant DNA methylation in cutaneous malignancies.
van Doorn R; Gruis NA; Willemze R; van der Velden PA; Tensen CP
Semin Oncol; 2005 Oct; 32(5):479-87. PubMed ID: 16210089
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous T Cell Lymphoma: A Difficult Diagnosis Demystified.
Peterson E; Weed J; Lo Sicco K; Latkowski JA
Dermatol Clin; 2019 Oct; 37(4):455-469. PubMed ID: 31466586
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
38. miR-155 expression in Primary Cutaneous T-Cell Lymphomas (CTCL).
Fava P; Bergallo M; Astrua C; Brizio M; Galliano I; Montanari P; Daprà V; Novelli M; Savoia P; Quaglino P; Fierro MT
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e27-e29. PubMed ID: 26935979
[No Abstract] [Full Text] [Related]
39. PLCG1 Gene Mutations in Cutaneous T-Cell Lymphomas Revisited.
Tensen CP
J Invest Dermatol; 2015 Sep; 135(9):2153-2154. PubMed ID: 26269406
[TBL] [Abstract][Full Text] [Related]
40. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
